ROCKET PHARMACEUTICALS, INC. financial data

Symbol
RCKT, RCKTW on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 730% % -12%
Debt-to-equity 17% % 12%
Return On Equity -66% % -2.9%
Return On Assets -56% % -1.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 108,569,143 shares 0.77%
Common Stock, Shares, Outstanding 108,319,783 shares 1.8%
Entity Public Float $212,500,000 USD -85%
Common Stock, Value, Issued $1,083,000 USD 1.7%
Weighted Average Number of Shares Outstanding, Basic 111,123,770 shares 17%
Weighted Average Number of Shares Outstanding, Diluted 111,123,770 shares 17%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $142,015,000 USD -17%
General and Administrative Expense $86,501,000 USD -15%
Operating Income (Loss) $231,747,000 USD 15%
Net Income (Loss) Attributable to Parent $223,123,000 USD 14%
Earnings Per Share, Basic -2.01 USD/shares 26%
Earnings Per Share, Diluted -2.01 USD/shares 26%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $77,558,000 USD -53%
Cash, Cash Equivalents, and Short-term Investments $188,900,000 USD -49%
Assets, Current $192,734,000 USD -49%
Property, Plant and Equipment, Net $28,170,000 USD -23%
Operating Lease, Right-of-Use Asset $3,210,000 USD -23%
Intangible Assets, Net (Excluding Goodwill) $25,150,000 USD 0%
Goodwill $39,154,000 USD 0%
Assets $330,449,000 USD -37%
Employee-related Liabilities, Current $12,294,000 USD 2.9%
Liabilities, Current $30,206,000 USD -26%
Operating Lease, Liability, Noncurrent $2,600,000 USD -20%
Other Liabilities, Noncurrent $1,060,000 USD -7.1%
Liabilities $53,228,000 USD -17%
Accumulated Other Comprehensive Income (Loss), Net of Tax $31,000 USD -147%
Retained Earnings (Accumulated Deficit) $1,441,239,000 USD -18%
Stockholders' Equity Attributable to Parent $277,221,000 USD -40%
Liabilities and Equity $330,449,000 USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $55,790,000 USD 1.9%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $58,035,000 USD -266%
Common Stock, Shares Authorized 180,000,000 shares 0%
Common Stock, Shares, Issued 108,319,783 shares 1.8%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $78,898,000 USD -52%
Deferred Tax Assets, Valuation Allowance $133,085,000 USD 3.1%
Operating Lease, Liability $3,603,000 USD -15%
Payments to Acquire Property, Plant, and Equipment $364,000 USD -82%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $223,220,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid $4,706,000 USD -18%
Property, Plant and Equipment, Gross $57,293,000 USD -1.3%
Operating Lease, Liability, Current $1,003,000 USD 0.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two $759,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,005,000 USD 0.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.0884 pure 0.23%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,103,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year Three $522,000 USD -31%
Deferred Tax Assets, Operating Loss Carryforwards $78,744,000 USD 17%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $539,000 USD 3.3%
Operating Lease, Payments $364,000 USD 9.3%
Additional Paid in Capital $1,717,408,000 USD 2.2%
Depreciation, Depletion and Amortization $2,700,000 USD 42%
Share-based Payment Arrangement, Expense $37,059,000 USD -16%
Interest Expense $1,891,000 USD 0.26%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%